## SEQUENCE LISTING

```
<110> APOGENIX Biotechnology AG
<120> Improved FC Fusion Proteins
<130> 31098PWO-HC
<140> PCT/EP2004/003239
<141> 2004-03-26
<150> PCT/2004/003239
<151> 2004-03-26
<160> 82
<170> PatentIn Ver. 2.1
<210> 1
<211> 30
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: PCR primer.
      for the amplification of CD95 cDNA
<220>
<223> Sense huCD95-Hind III
<400> 1
tataaagctt gccaccatgc tgggcatctg
                                                                   30
<210> 2
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: PCR primer for
      the amplification of CD95 cDNA
<220>
<223> Antisense huCD95-BgI II
<400> 2
tataagatct ggatccttcc tctttgc
                                                                   27
<210> 3
<211> 30
<212> DNA
<213> Artificial Sequence.
<220>
<223> Description of Artificial Sequence: PCR primer
```

## for the amplification of IgG1 Fc cDNA

<220> <223>	Sense hulgG1Fc-BgIII	
<400> tataa	3 gatct tgtgacaaaa ctcacacatg	30
		•
<210> <211>		
<212> <213>	DNA Artificial Sequence	
<220>		
_	Description of Artificial Sequence: PCR primer for the amplification of IgG1 Fc cDNA	
<220> <223>	Antisense hulgG1Fc-XhoI	
<400>	4	
tatact	cgag tcatttaccc ggagacaggg	30
<210>	5	
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence: PCR primer for the changing the Kozak Sequence from GCCACCATGC to GCCGCCACCATGG	
<220>		
<223>	ShuCD95EC_altKozak	
· <400>	ፍ	
	agett geegeeacea tggtgggeat e	31
<210>	· ·	
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence: PCR primer for the changing the Kozak Sequence from GCCACCATGC to GCCGCCACCATGG	
<220>		
<223>	AS698 hulgGlFc-Xho1	
<400>	6 .	•
tatact	cgag tcatttaccc ggagacaggg	30

```
<210> 7
<211> 38
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer for
      amplifying cDNA of human IgG1 Fc (partial hinge
      CH3)
<220>
<223> Sense_hulgG1
<400> 7
ccagggactc ctgcctcttg tgacaaaact cacacatg
                                                                   38
<210> 8
<211> 30
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer for
      amplifying cDNA of human IgG1 Fc (partial hinge
      CH3)
<220>
<223> Antisense_ERIhulgG1
<400> 8
tatagaatte teatttacce ggagacaggg
                                                                    30
<210> 9
<211> 40
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer used to
      amplify the cDNA of TRAILR2 domain
<220>
<223> Sense_HIII_TRAILR2
<400> 9
tataaagctt gccgccacca tggaacaacg gggacagaac
                                                                   40
<210> 10
<211> 33
<212> DNA
```

<213> Artificial Sequence

```
<220>
<223> Description of Artificial Sequence: primer used to
      amplify the cDNA of TRAILR2 domain
<220>
<223> Antisense_TRAILR2
<400> 10
gtgagttttg tcacaagagg caggagtccc tgg
                                                                   33
<210> 11
<211> 40
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer for PCR
      used to utlilize fragments for cloning purposes
<220>
<223> Sense_HIII_TRAILR2
<400> 11
tataaagctt gccgccacca tggaacaacg gggacagaac
                                                                   40
<210> 12
<211> 30
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer for
      PCR used to utlilize fragments for cloning
      purposes
<220>
<223> Antisense_ERIhulgG1
<400> 12
tatagaattc tcatttaccc ggagacaggg
                                                                   30
<210> 13
<211> 335
<212> PRT
<213> human
<220>
<223> CD95 >sp/P25445/TNR6_HUMAN Tumor necrosis factor
      receptor superfamily 6 precursor (FASL-receptor)
      (Apoptosis-mediating surface antigen FAS) (Apo-1
      antigen) (CD95) - Homo sapiens (Human)
<400> 13
```

Met Leu Gly Ile Trp Thr Leu Leu Pro Leu Val Leu Thr Ser Val Ala

1

Arg Leu Ser Ser Lys Ser Val Asn Ala Gln Val Thr Asp Ile Asn Ser 20 25 30

Lys Gly Leu Glu Leu Arg Lys Thr Val Thr Thr Val Glu Thr Gln Asn 35 40 45

Leu Glu Gly Leu His His Asp Gly Gln Phe Cys His Lys Pro Cys Pro 50 60

Pro Gly Glu Arg Lys Ala Arg Asp Cys Thr Val Asn Gly Asp Glu Pro 65 70 75 80

Asp Cys Val Pro Cys Gln Glu Gly Lys Glu Tyr Thr Asp Lys Ala His
85 90 95

Phe Ser Ser Lys Cys Arg Arg Cys Arg Leu Cys Asp Glu Gly His Gly 100 105 110

Leu Glu Val Glu Ile Asn Cys Thr Arg Thr Gln Asn Thr Lys Cys Arg 115 120 125

Cys Lys Pro Asn Phe Phe Cys Asn Ser Thr Val Cys Glu His Cys Asp 130 135 140

Pro Cys Thr Lys Cys Glu His Gly Ile Ile Lys Glu Cys Thr Leu Thr 145 150 155 160

Ser Asn Thr Lys Cys Lys Glu Glu Gly Ser Arg Ser Asn Leu Gly Trp
165 170 175

Leu Cys Leu Leu Leu Pro Ile Pro Leu Ile Val Trp Val Lys Arg 180 185 190

Lys Glu Val Gln Lys Thr Cys Arg Lys His Arg Lys Glu Asn Gln Gly
195 200 205

Ser His Glu Ser Pro Thr Leu Asn Pro Glu Thr Val Ala Ile Asn Leu 210 215 220

Ser Asp Val Asp Leu Ser Lys Tyr Ile Thr Thr Ile Ala Gly Val Met 225 230 235 240

Thr Leu Ser Gln Val Lys Gly Phe Val Arg Lys Asn Gly Val Asn Glu 245 250 255

Ala Lys Ile Asp Glu Ile Lys Asn Asp Asn Val Gln Asp Thr Ala Glu 260 265 270

Gln Lys Val Gln Leu Leu Arg Asn Trp His Gln Leu His Gly Lys Lys 275 280 285

Glu Ala Tyr Asp Thr Leu Ile Lys Asp Leu Lys Lys Ala Asn Leu Cys 290 295 300

Thr Leu Ala Glu Lys Ile Gln Thr Ile Ile Leu Lys Asp Ile Thr Ser

Asp Ser Glu Asn Ser Asn Phe Arg Asn Glu Ile Gln Ser Leu Val
325 330 335

<210> 14

<211> 330

<212> PRT

<213> human

<220>

<223> IgG1 > sp/P01857/GC1\_HUMAN Ig gamma-1 chain C
 region - Homo sapiens (Human)

<400> 14

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 . 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 150 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly

210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 225 230 235 240

Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330

<210> 15

í i

<211> 400

<212> PRT

<213> Artificial Sequence

<220>

<221> MUTAGEN

<222> (1)..(400)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 15

Met Leu Gly Ile Trp Thr Leu Leu Pro Leu Val Leu Thr Ser Val Ala 1 5 10 15

Arg Leu Ser Ser Lys Ser Val Asn Ala Gln Val Thr Asp Ile Asn Ser 20 25 30

Lys Gly Leu Glu Leu Arg Lys Thr Val Thr Thr Val Glu Thr Gln Asn 35 40 45

Leu Glu Gly Leu His His Asp Gly Gln Phe Cys His Lys Pro Cys Pro 50 60

Pro Gly Glu Arg Lys Ala Arg Asp Cys Thr Val Asn Gly Asp Glu Pro 65 70 75 80

Asp Cys Val Pro Cys Gln Glu Gly Lys Glu Tyr Thr Asp Lys Ala His

Phe Ser Ser Lys Cys Arg Arg Cys Arg Leu Cys Asp Glu Gly His Gly
100 105 . 110

Leu Glu Val Glu Ile Asn Cys Thr Arg Thr Gln Asn Thr Lys Cys Arg 115 120 125

Cys Lys Pro Asn Phe Phe Cys Asn Ser Thr Val Cys Glu His Cys Asp 130 135 140

Pro Cys Thr Lys Cys Glu His Gly Ile Ile Lys Glu Cys Thr Leu Thr 145 150 155 160

Ser Asn Thr Lys Cys Lys Glu Glu Gly Ser Arg Ser Cys Asp Lys Thr 165 170 175

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 180 185 190

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 195 200 205

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 210 220

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 225 230 235 240

Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
245 250 255

Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 260 265 270

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 275 280 285

Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 290 295 300

Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 305 310 315 320

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 325 330 335

Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 340 345 350

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 355

Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 370 375 380

Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 395 390 400

```
<211> 43
<212> PRT
<213> human
<220>
<223> CD95 extracellular domain
                                 (AA 131-173)
<400> 16
Pro Asn Phe Phe Cys Asn Ser Thr Val Cys Glu His Cys Asp Pro Cys
  1
                                      10
                                                           15
Thr Lys Cys Glu His Gly Ile Ile Lys Glu Cys Thr Leu Thr Ser Asn
              20
                                                       30
Thr Lys Cys Lys Glu Glu Gly Ser Arg Ser Asn
          35
<210> 17
<211> 22
<212> PRT
<213> human
<220>
<223> huIgG1 (AA 99-120)
<400> 17
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
  1
                                      10
                                                           15
                   5
Pro Glu Leu Leu Gly Gly
              20
<210> 18
<211> 60
<212> PRT
<213> Artificial Sequence
<220>
 <223> CD95-Fc fusion protein of CD95 extracellular
       domain (AA 131-173) and huIgG1 (AA99-120) with an
       overlapping amino acid (CD95 AA 172 and huIgG1 AA
       102)
<220>
 <223> Description of Artificial Sequence:
```

<210> 16

protein

<400> 18

Pro Asn Phe Phe Cys Asn Ser Thr Val Cys Glu His Cys Asp Pro Cys
1 10 15

Thr Lys Cys Glu His Gly Ile Ile Lys Glu Cys Thr Leu Thr Ser Asn 20 25 30

Thr Lys Cys Lys Glu Glu Gly Ser Arg Ser Cys Asp Lys Thr His Thr
35 40 45

Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 50 55 60

<210> 19

<211> 468

<212> PRT

<213> human

<220>

<223> TRAIL-R1 >sp/000220/T10A\_HUMAN Tumor necrosis
 factor receptor superfamily member 10A precursor
 (Death receptor 4) (TNF-related
 apoptosis-including ligand receptor 1) (TRAIL
 receptor-1) (TRAIL-R1)

<400> 19

Met Ala Pro Pro Pro Ala Arg Val His Leu Gly Ala Phe Leu Ala Val 1 5 10

Thr Pro Asn Pro Gly Ser Ala Ala Ser Gly Thr Glu Ala Ala Ala Ala 20 25 30

Thr Pro Ser Lys Val Trp Gly Ser Ser Ala Gly Arg Ile Glu Pro Arg
35 40 45

Gly Gly Gly Arg Gly Ala Leu Pro Thr Ser Met Gly Gln His Gly Pro 50 60

Ser Ala Arg Ala Gly Arg Ala Pro Gly Pro Arg Pro Ala Arg 65 70 75 80

Glu Ala Ser Pro Arg Leu Arg Val His Lys Thr Phe Lys Phe Val Val 85 90 95

Val Gly Val Leu Leu Gln Val Val Pro Ser Ser Ala Ala Thr Ile Lys 100 105 110

Leu His Asp Gln Ser Ile Gly Thr Gln Gln Trp Glu His Ser Pro Leu 115 120 125

Gly Glu Leu Cys Pro Pro Gly Ser His Arg Ser Glu His Pro Gly Ala 130 135 140

Cys Asn Arg Cys Thr Glu Gly Val Gly Tyr Thr Asn Ala Ser Asn Asn

Leu Phe Ala Cys Leu Pro Cys Thr Ala Cys Lys Ser Asp Glu Glu Glu 175

Arg Ser Pro Cys Thr Thr Thr Arg Asn Thr Ala Cys Gln Cys Lys Pro 180 . 185 . 190

Gly Thr Phe Arg Asn Asp Asn Ser Ala Glu Met Cys Arg Lys Cys Ser 195 200 205

Arg Gly Cys Pro Arg Gly Met Val Lys Val Lys Asp Cys Thr Pro Trp 210 220

Ser Asp Ile Glu Cys Val His Lys Glu Ser Gly Asn Gly His Asn Ile 225 230 235 240

Trp Val Ile Leu Val Val Thr Leu Val Val Pro Leu Leu Leu Val Ala 245 250 255

Val Leu Ile Val Cys Cys Cys Ile Gly Ser Gly Cys Gly Gly Asp Pro 260 265 270

Lys Cys Met Asp Arg Val Cys Phe Trp Arg Leu Gly Leu Leu Arg Gly 275 280 285

Pro Gly Ala Glu Asp Asn Ala His Asn Glu Ile Leu Ser Asn Ala Asp 290 295 300

Ser Leu Ser Thr Phe Val Ser Glu Gln Gln Met Glu Ser Gln Glu Pro 305 310 315 320

Ala Asp Leu Thr Gly Val Thr Val Gln Ser Pro Gly Glu Ala Gln Cys 325 330 335

Leu Leu Gly Pro Ala Glu Ala Glu Gly Ser Gln Arg Arg Leu Leu 340 345 350

Val Pro Ala Asn Gly Ala Asp Pro Thr Glu Thr Leu Met Leu Phe Phe . 355 360 365

Asp Lys Phe Ala Asn Ile Val Pro Phe Asp Ser Trp Asp Gln Leu Met 370 380

Arg Gln Leu Asp Leu Thr Lys Asn Glu Ile Asp Val Val Arg Ala Gly 385 390 395 400

Thr Ala Gly Pro Gly Asp Ala Leu Tyr Ala Met Leu Met Lys Trp Val
405 410 415

Asn Lys Thr Gly Arg Asn Ala Ser Ile His Thr Leu Leu Asp Ala Leu 420 425 430

Glu Arg Met Glu Glu Arg His Ala Lys Glu Lys Ile Gln Asp Leu Leu 435 440 445

Val Asp Ser Gly Lys Phe Ile Tyr Leu Glu Asp Gly Thr Gly Ser Ala

Val Ser Leu Glu 465

<210> 20

<211> 39

<212> PRT

<213> human

<220>

<223> Trail R1 extracellular domain (AA 201-239)

<400> 20

Ala Glu Met Cys Arg Lys Cys Ser Arg Gly Cys Pro Arg Gly Met Val 1 5 10

Lys Val Lys Asp Cys Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys
20 25 30

Glu Ser Gly Asn Gly His Asn 35

<210> 21

<211> 54

<212> PRT

<213> Artificial Sequence

<220>

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 21

Ala Glu Met Cys Arg Lys Cys Ser Arg Gly Cys Pro Arg Gly Met Val 1 5 10

Lys Val Lys Asp Cys Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys
20 25 30

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 35 40 45

Pro Glu Leu Leu Gly Gly 50

```
<211> 51
<212> PRT
<213> Artificial Sequence
<220>
<223> Trail-R1-Fc fusion protein of Trail R1
      extracellular domain (AA 201-239) and huIgG1 (AA
      99-120) with an overlapping amino acid (TRAILR1 AA
      232 and huIgG1 AA 101)
<220>
<223> Description of Artificial Sequence: fusion protein
<400> 22.
Ala Glu Met Cys Arg Lys Cys Ser Arg Gly Cys Pro Arg Gly Met Val
  1
                                      10
Lys Val Lys Asp Cys Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys
             20
                                  25
                                                      30
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
         35
                                                  45
Leu Gly Gly
     50
<210> 23
<211> 52
<212> PRT
<213> Artificial Sequence
<223> Trail-R1-Fc fusion protein of Trail R1
      extracellular domain (AA 201-239) and huIgG1
      (AA99-120) with an overlapping amino acid (TRAILR1
     AA 234 and huIgG1 AA 102)
<220>
<223> Description of Artificial Sequence: fusion protein
<400> 23
Ala Glu Met Cys Arg Lys Cys Ser Arg Gly Cys Pro Arg Gly Met Val
```

10

Lys Val Lys Asp Cys Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys

Glu Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu

40

25

1

20

35

Leu Leu Gly Gly

50

15

15

30

```
<210> 24
<211> 51
<212> PRT
<213> Artificial Sequence
<220>
<223> Trail-R1-Fc fusion protein of Trail R1
     extracellular domain (AA 201-239) and hulgGl
      (AA99-120) with an overlapping amino acid (TRAILR1
      AA 238 and huIgG1 AA 107)
<220>
<223> Description of Artificial Sequence: fusion protein
<400> 24
Ala Glu Met Cys Arg Lys Cys Ser Arg Gly Cys Pro Arg Gly Met Val
  1
                                      10
                                                          15
Lys Val Lys Asp Cys Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys
             20
                                                      30
                                  25
Glu Ser Gly Asn Gly His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
         35
                              40
                                                  45
Leu Gly Gly
     50
<210> 25
<211> 440
<212> PRT
<213> human
<220>
<223> Trail-R2 >sp/014763/T10B HUMAN Tumor necrosis
      factor receptor superfamily member 10B precursor
      (Death receptor 5) (TNF-related
      apoptosis-including ligand receptor 2) (TRAIL
      receptor-2) (TRAIL-R2)
<400> 25
Met Glu Gln Arg Gly Gln Asn Ala Pro Ala Ala Ser Gly Ala Arg Lys
                                      10
Arg His Gly Pro Gly Pro Arg Glu Ala Arg Gly Ala Arg Pro Gly Pro
             20
                                  25
                                                      30
Arg Val Pro Lys Thr Leu Val Leu Val Val Ala Ala Val Leu Leu Leu
                                                  45
         35
                              40
Val Ser Ala Glu Ser Ala Leu Ile Thr Gln Gln Asp Leu Ala Pro Gln
     50
                         55
                                              60
Gln Arg Ala Ala Pro Gln Gln Lys Arg Ser Ser Pro Ser Glu Gly Leu
 65
                                          75
                      70
                                                              80
```

Cys Pro Pro Gly His His Ile Ser Glu Asp Gly Arg Asp Cys Ile Ser 85 90 95

3 #

Cys Lys Tyr Gly Gln Asp Tyr Ser Thr His Trp Asn Asp Leu Leu Phe 100 105 110

Cys Leu Arg Cys Thr Arg Cys Asp Ser Gly Glu Val Glu Leu Ser Pro 115 120 125

Cys Thr Thr Arg Asn Thr Val Cys Gln Cys Glu Glu Gly Thr Phe 130 135 140

Arg Glu Glu Asp Ser Pro Glu Met Cys Arg Lys Cys Arg Thr Gly Cys 145 150 155 160

Pro Arg Gly Met Val Lys Val Gly Asp Cys Thr Pro Trp Ser Asp Ile 165 170 175

Glu Cys Val His Lys Glu Ser Gly Thr Lys His Ser Gly Glu Ala Pro 180 185 190

Ala Val Glu Glu Thr Val Thr Ser Ser Pro Gly Thr Pro Ala Ser Pro 195 200 205

Cys Ser Leu Ser Gly Ile Ile Ile Gly Val Thr Val Ala Ala Val Val 210 215 220

Leu Ile Val Ala Val Phe Val Cys Lys Ser Leu Leu Trp Lys Lys Val 225 230 235 240

Leu Pro Tyr Leu Lys Gly Ile Cys Ser Gly Gly Gly Gly Asp Pro Glu 245 250 255

Arg Val Asp Arg Ser Ser Gln Arg Pro Gly Ala Glu Asp Asn Val Leu 260 265 270

Asn Glu Ile Val Ser Ile Leu Gln Pro Thr Gln Val Pro Glu Gln Glu 275 280 285

Met Glu Val Gln Glu Pro Ala Glu Pro Thr Gly Val Asn Met Leu Ser 290 295 300

Pro Gly Glu Ser Glu His Leu Leu Glu Pro Ala Glu Ala Glu Arg Ser 305 310 315 320

Gln Arg Arg Leu Leu Val Pro Ala Asn Glu Gly Asp Pro Thr Glu
325 330 335

Thr Leu Arg Gln Cys Phe Asp Asp Phe Ala Asp Leu Val Pro Phe Asp 340 345 350

Ser Trp Glu Pro Leu Met Arg Lys Leu Gly Leu Met Asp Asn Glu Ile 355 360 365

Lys Val Ala Lys Ala Glu Ala Ala Gly His Arg Asp Thr Leu Tyr Thr 370 380

Met Leu Ile Lys Trp Val Asn Lys Thr Gly Arg Asp Ala Ser Val His 385 390 395 400

Thr Leu Leu Asp Ala Leu Glu Thr Leu Gly Glu Arg Leu Ala Lys Gln
405
410
415

Lys Ile Glu Asp His Leu Leu Ser Ser Gly Lys Phe Met Tyr Leu Glu 420 425 430

Gly Asn Ala Asp Ser Ala Met Ser 435 440

<210> 26

g . 8

<211> 40

<212> PRT

<213> human

<220>

<400> 26

Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys Glu Ser Gly Thr Lys

1 10 15

His Ser Gly Glu Ala Pro Ala Val Glu Glu Thr Val Thr Ser Ser Pro 20 25 30

Gly Thr Pro Ala Ser Pro Cys Ser 35

<210> 27

<211> 58

<212> PRT

<213> Artificial Sequence

<220>

<223> Trail-R2(long)-Fc fusion protein of Trail R1
 extracellular domain (AA 171-210)Trail R2 (long)
 extracellular domain (AA 171-210), "repeat"
 included) and huIgGl (AA99-120) with an
 overlapping amino acid

<220>

<223> Trail-R2(long)-Fc fusion protein of Trail R2
 extracellular domain (AA 171-210; "repeat"
 included) and huIgG1 (AA99-120) with an
 overlapping amino acid (TRAIL-R2(long) AA 210 and
 huIgG1 AA 102)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 27

. .

Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys Glu Ser Gly Thr Lys

1 10 15

His Ser Gly Glu Ala Pro Ala Val Glu Glu Thr Val Thr Ser Ser Pro-20 25 30

Gly Thr Pro Ala Ser Pro Cys Ser Cys Asp Lys Thr His Thr Cys Pro 35 40 45

Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 50

<210> 28

<211> 55

<212> PRT

<213> Artificial Sequence

<220>

<223> Trail-R2(long)-Fc fusion protein of Trail R2
 extracellular domain (AA 171-210; "repeat"
 included) and huIgG1 (AA99-120) with an
 overlapping amino acid (TRAIL-R2(long) AA 207 and
 huIgG1 AA 102)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 28

Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys Glu Ser Gly Thr Lys

1 10 15

His Ser Gly Glu Ala Pro Ala Val Glu Glu Thr Val Thr Ser Ser Pro 20 25 30

Gly Thr Pro Ala Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 35 40 45

Ala Pro Glu Leu Leu Gly Gly 50

<210> 29

<211> 58

<212> PRT

<213> Artificial Sequence

<220>

<223> Trail-R2(long)-Fc fusion protein of Trail R2
 extracellular domain (AA 171-210; "repeat"
 included) and huIgG1 (AA99-120) with an
 overlapping amino acid (TRAIL-R2(long) AA 208 and
 huIgG1 AA 100)

```
<220>
```

<223> Description of Artificial Sequence: fusion protein

<400> 29

Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys Glu Ser Gly Thr Lys

1 10 15

His Ser Gly Glu Ala Pro Ala Val Glu Glu Thr Val Thr Ser Ser Pro 20 25 30

Gly Thr Pro Ala Ser Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
35 40 45

Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 50

<210> 30

<211> 55

<212> PRT

<213> Artificial Sequence

<220>

<223> Trail-R2(long)-Fc fusion protein of Trail R2
 extracellular domain (AA 171-210; "repeat"
 included) and huIgG1 (AA99-120) with an
 overlapping amino acid (TRAIL-R2(long) AA 205 and
 huIgG1 AA 100)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 30

Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys Glu Ser Gly Thr Lys
1 10 15

His Ser Gly Glu Ala Pro Ala Val Glu Glu Thr Val Thr Ser Ser Pro 20 25 30 ·

Gly Thr Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 35 40 45

Ala Pro Glu Leu Leu Gly Gly 50

<210> 31

<211> 56

<212> PRT

<213> Artificial Sequence

<220>

<223> Trail-R2(long)-Fc fusion protein of Trail R1
 extracellular domain (AA 171-210; "repeat"
 included) and huIgG1 (AA99-120) with an

overlapping amino acid (TRAIL-R2(long) AA 209 and hulgGl AA 103)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 31

Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys Glu Ser Gly Thr Lys

1 10 15

His Ser Gly Glu Ala Pro Ala Val Glu Glu Thr Val Thr Ser Ser Pro 20 25 30

Gly Thr Pro Ala Ser Pro Cys Asp Lys Thr His Thr Cys Pro Pro Cys
35 40 45

Pro Ala Pro Glu Leu Leu Gly Gly 50

<210> 32

<211> 48

<212> PRT

<213> Artificial Sequence

<220>

<223> Trail-R2(long)-Fc fusion protein of Trail R2
 extracellular domain (AA 171-210; "repeat"
 included) and huIgG1 (AA99-120) with an
 overlapping amino acid (TRAIL-R2(long) AA 204 and
 huIgG1 AA 106)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 32

Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys Glu Ser Gly Thr Lys
1 10 15

His Ser Gly Glu Ala Pro Ala Val Glu Glu Thr Val Thr Ser Ser Pro 20 25 30

Gly Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 35 40 45

<210> 33

<211> 21

<212> PRT

<213> human

<220>

```
<223> Trail R2 (long) extracellular domain (AA 171-191;
      "repeat" not included)
<400> 33
Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys Glu Ser Gly Thr Lys
                                      10
  1
                  5
                                                          15
His Ser Gly Glu Ala
             20
<210> 34
<211> 41
<212> PRT
<213> Artificial Sequence
<220>
<223> Trail-R2(long)-Fc fusion protein of Trail R2
      (long) extracellular domain (AA 171-191; "repeat"
      not included) and huIgG1 (AA99-120) with an
      overlapping amino acid (TRAIL-R2(long) AA190 and
      huIgG1 AA99)
<220>
<223> Description of Artificial Sequence: fusion protein
<400> 34
Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys Glu Ser Gly Thr Lys
                                                          15
  1
                   5
                                      10
His Ser Gly Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro
             20
                                  2,5
                                                       30
Cys Pro Ala Pro Glu Leu Leu Gly Gly
         35
<210> 35
<211> 35
<212> PRT
<213> Artificial Sequence
<220>
<223> Trail-R2(long)-Fc fusion protein of Trail R2
      (long) extracellular domain (AA171-191; "repeat"
      not included) and huIgG1 (AA99-120) with an
      overlapping amino acid (TRAIL-R2(long) AA186 and
      huIgG1 AA101)
<220>
<223> Description of Artificial Sequence: fusion protein
<400> 35
Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys Glu Ser Gly Thr Lys
                                                         . 15
                                      10
  1
```

.5 4

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 20 25 30

Leu Gly Gly 35

<210> 36

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Trail-R2(long)-Fc fusion protein of Trail R2
 (long) extracellular domain (AA171-191; "repeat"
 not included) and huIgG1 (AA99-120) with an
 overlapping amino acid (TRAIL-R2(long) AA188 and
 huIgG1 AA102)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 36

Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys Glu Ser Gly Thr Lys

1 10 15

His Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 20 25 30

Leu Leu Gly Gly 35

<210> 37

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 37

Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys Glu Ser Gly Thr His 1 5 10 15

Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 20

```
<210> 38
<211> 30
<212> PRT
<213> Artificial Sequence
<220>
<223> Trail-R2(long)-Fc fusion protein of Trail R2
      (long) extracellular domain (AA171-191; "repeat"
      not included) and huIgG1 (AA99-120) with an
      overlapping amino acid (TRAIL-R2(long) AA187 and
      huIgG1 AA107)
<220>
<223> Description of Artificial Sequence: fusion protein
<400> 38
Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys Glu Ser Gly Thr Lys
  1
                                                          15
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
             20
                                 25
                                                      30
<210> 39
<211> 411
<212> PRT
<213> human
<220>
<223> Trail-R2 (short) >sp/014763/T10B_HUMAN Tumor
      necrosis factor receptor superfamily 10B precursor
      (Death receptor 5) (TNF-related apoptosis-inducing
      ligand receptor 2) (TRAIL receptor-2) (TRAIL-R2)
<400> 39
Met Glu Gln Arg Gly Gln Asn Ala Pro Ala Ala Ser Gly Ala Arg Lys
                                      10
Arg His Gly Pro Gly Pro Arg Glu Ala Arg Gly Ala Arg Pro Gly Pro
             20
Arg Val Pro Lys Thr Leu Val Leu Val Val Ala Ala Val Leu Leu Leu
         35
Val Ser Ala Glu Ser Ala Leu Ile Thr Gln Gln Asp Leu Ala Pro Gln
     50
                         55
                                              60
Gln Arg Ala Pro Gln Gln Lys Arg Ser Ser Pro Ser Glu Gly Leu
                     70
                                          75
                                                              80
 65
```

Cys Pro Pro Gly His His Ile Ser Glu Asp Gly Arg Asp Cys Ile Ser

90

85

Cys Lys Tyr Gly Gln Asp Tyr Ser Thr His Trp Asn Asp Leu Leu Phe 100 105 110

Cys Leu Arg Cys Thr Arg Cys Asp Ser Gly Glu Val Glu Leu Ser Pro 115 120 125

Cys Thr Thr Arg Asn Thr Val Cys Gln Cys Glu Glu Gly Thr Phe 130 135 140

Arg Glu Glu Asp Ser Pro Glu Met Cys Arg Lys Cys Arg Thr Gly Cys 145 150 155 160

Pro Arg Gly Met Val Lys Val Gly Asp Cys Thr Pro Trp Ser Asp Ile 165 170 175

Glu Cys Val His Lys Glu Ser Gly Ile Ile Ile Gly Val Thr Val Ala 180 185 190

Ala Val Val Leu Ile Val Ala Val Phe Val Cys Lys Ser Leu Leu Trp 195 200 205

Lys Lys Val Leu Pro Tyr Leu Lys Gly Ile Cys Ser Gly Gly Gly 210 215 220

Asp Pro Glu Arg Val Asp Arg Ser Ser Gln Arg Pro Gly Ala Glu Asp 225 230 235 240

Asn Val Leu Asn Glu Ile Val Ser Ile Leu Gln Pro Thr Gln Val Pro 245 250 255

Glu Gln Glu Met Glu Val Gln Glu Pro Ala Glu Pro Thr Gly Val Asn 260 265 270

Met Leu Ser Pro Gly Glu Ser Glu His Leu Leu Glu Pro Ala Glu Ala 275 280 285

Glu Arg Ser Gln Arg Arg Leu Leu Val Pro Ala Asn Glu Gly Asp 290 295 300

Pro Thr Glu Thr Leu Arg Gln Cys Phe Asp Asp Phe Ala Asp Leu Val 305 310 315 320

Pro Phe Asp Ser Trp Glu Pro Leu Met Arg Lys Leu Gly Leu Met Asp 325 330 335

Asn Glu Ile Lys Val Ala Lys Ala Glu Ala Ala Gly His Arg Asp Thr 340 345 350

Leu Tyr Thr Met Leu Ile Lys Trp Val Asn Lys Thr Gly Arg Asp Ala 355 360 365

Ser Val His Thr Leu Leu Asp Ala Leu Glu Thr Leu Gly Glu Arg Leu 370 380

Ala Lys Gln Lys Ile Glu Asp His Leu Leu Ser Ser Gly Lys Phe Met 385 390 395 400

```
Tyr Leu Glu Gly Asn Ala Asp Ser Ala Met Ser
405 410
```

<210> 40 <211> 34 <212> PRT <213> human <220> <223> Trail-R2 (short) extracellular domain (AA 151 - AA 184) <400> 40 Glu Met Cys Arg Lys Cys Arg Thr Gly Cys Pro Arg Gly Met Val Lys 1 15 . 10 Val Gly Asp Cys Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys Glu 20 30 Ser Gly <210> 41 <211> 53 <212> PRT <213> Artificial Sequence <220> <223> Trail-R2(short)-Fc fusion protein of Trail R2 (short) extracellular domain (AA 151-184) and hulgG1 (AA 99-120) with an overlapping amino acid (TRAIL-R2(short) AA 182 and huIgG1 AA 99) <220> <223> Description of Artificial Sequence: fusion protein <400> 41 Glu Met Cys Arg Lys Cys Arg Thr Gly Cys Pro Arg Gly Met Val Lys Val Gly Asp Cys Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys Glu 20 30 25 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro

Glu Leu Leu Gly Gly 50

35

<210> 42 <211> 50 <212> PRT

<213> Artificial Sequence

<220,>

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 42

Glu Met Cys Arg Lys Cys Arg Thr Gly Cys Pro Arg Gly Met Val Lys
1 10 15

Val Gly Asp Cys Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys Ser 20 25 30

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 35 40 45

Gly Gly 50

<210> 43

<211> 51

<212> PRT

<213> Artificial Sequence

<220>

<223> Trail-R2(short)-Fc fusion protein of Trail R2
 (short) extracellular domain (AA 151-184) and
 huIgG1 (AA 99-120) with an overlapping amino acid
 (TRAIL-R2(short) AA 183 and huIgG1 AA 102)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 43

Glu Met Cys Arg Lys Cys Arg Thr Gly Cys Pro Arg Gly Met Val Lys
1 5 10 15

Val Gly Asp Cys Thr Pro Trp Ser Asp Ile Glu Cys Val His Lys Glu 20 25 30

Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
35 40 45

Leu Gly Gly 50

```
<211> 43
<212> PRT
<213> Artificial Sequence
<220>
<223> Trail-R2(short)-Fc fusion protein of Trail R2
       (short) extracellular domain (AA 151-184) and
      huIgG1 (AA 99-120) with an overlapping amino acid
       (TRAIL-R2(short) AA 180 and huIgG1 AA 107)
<220>
<223> Description of Artificial Sequence: fusion protein
<400> 44
Glu Met Cys Arg Lys Cys Arg Thr Gly Cys Pro Arg Gly Met Val Lys
                                                           15
   1
Val Gly Asp Cys Thr Pro Trp Ser Asp Ile Glu Cys Val His Thr Cys
              20
                                                       30
Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
          35
                              40
<210> 45
<211> 259
<212> PRT
<213> Artificial Sequence
<220>
<223> Trail-R3>sp/014798/T10C_HUMAN Tumor necrosis
       factor receptor superfamily member 10C
       precursor; Decoy receptor 1; DcR1; Decoy TRAIL
       receptor without death domain; TNF-related
       apoptosis inducing ligand r3
<220>
<223> Description of Artificial Sequence: fusion protein
<400> 45
Met Ala Arg Ile Pro Lys Thr Leu Lys Phe Val Val Val Ile Val Ala
                                       10
                                                           15.
Val Leu Leu Pro Val Leu Ala Tyr Ser Ala Thr Thr Ala Arg Gln Glu
              20
                                                       30
Glu Val Pro Gln Gln Thr Val Ala Pro Gln Gln Gln Arg His Ser Phe
          35
                                                   45
```

Lys Gly Glu Glu Cys Pro Ala Gly Ser His Arg Ser Glu His Thr Gly

Ala Cys Asn Pro Cys Thr Glu Gly Val Asp Tyr Thr Asn Ala Ser Asn

Asn Glu Pro Ser Cys Phe Pro Cys Thr Val Cys Lys Ser Asp Gln Lys

55

70

60

80

50

His Lys Ser Ser Cys Thr Met Thr Arg Asp Thr Val Cys Gln Cys Lys
100 105 110

Glu Gly Thr Phe Arg Asn Glu Asn Ser Pro Glu Met Cys Arg Lys Cys
115 120 125

Ser Arg Cys Pro Ser Gly Glu Val Gln Val Ser Asn Cys Thr Ser Trp 130 135 140

Asp Asp Ile Gln Cys Val Glu Glu Phe Gly Ala Asn Ala Thr Val Glu 145 150 155 160

Thr Pro Ala Ala Glu Glu Thr Met Asn Thr Ser Pro Gly Thr Pro Ala 165 170 175

Pro Ala Ala Glu Glu Thr Met Asn Thr Ser Pro Gly Thr Pro Ala Pro 180 185 190

Ala Ala Glu Glu Thr Met Thr Thr Ser Pro Gly Thr Pro Ala Pro Ala 195 200 205

Ala Glu Glu Thr Met Thr Thr Ser Pro Gly Thr Pro Ala Pro Ala Ala 210 215 220

Glu Glu Thr Met Thr Thr Ser Pro Gly Thr Pro Ala Ser Ser His Tyr 225 230 235 240

Leu Ser Cys Thr Ile Val Gly Ile Ile Val Leu Ile Val Leu Leu Ile 245 250 255

Val Phe Val

<210> 46

<211> 36

<212> PRT

<213> human

<220>

<223> Trail-R3 extracellular domain (AA 201-236;
 "repeats" included)

<400> 46

Ser Pro Gly Thr Pro Ala Pro Ala Ala Glu Glu Thr Met Thr Thr Ser
1 5 10 15

Pro Gly Thr Pro Ala Pro Ala Ala Glu Glu Thr Met Thr Thr Ser Pro 20 25 30

Gly Thr Pro Ala

```
<210> 47
<211> 55
<212> PRT
<213> Artificial Sequence
<220>
<223> Trail-R3-Fc fusion protein of Trail-R3
      extracellular domain (AA 201-236; "repeats"
      included) and huIgGl (AA 99-120) with an
      overlapping amino acid (TRAIL-R3 AA 235 and huIgG1
      AA 100)
<220>
<223> Description of Artificial Sequence: fusion protein
<400> 47
Ser Pro Gly Thr Pro Ala Pro Ala Ala Glu Glu Thr Met Thr Ser
  1
                                                          15
                                      10
Pro Gly Thr Pro Ala Pro Ala Ala Glu Glu Thr Met Thr Thr Ser Pro
             20
                                                      30
                                 25
Gly Thr Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
         35
                             40
                                                  45
Ala Pro Glu Leu Leu Gly Gly
     50
                         55
<210> 48
<211> 52
<212> PRT
<213> Artificial Sequence
<220>
<223> Trail-R3-Fc fusion protein of Trail-R3
      extracellular domain (AA 201-236; "repeats"
      included) and huIgG1 (AA 99-120) with an
      overlapping amino acid (TRAIL-R3 AA 232and hulgG1
      AA 100)
<220>
<223> Description of Artificial Sequence: fusion protein
<400> 48
Ser Pro Gly Thr Pro Ala Pro Ala Ala Glu Glu Thr Met Thr Ser
  1
                                     10
                                                          15
Pro Gly Thr Pro Ala Pro Ala Ala Glu Glu Thr Met Thr Thr Ser Pro
             20
                                                      30
                                 25
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
         35
                             40
                                                  45
```

Leu Leu Gly Gly

<210> 49 <211> 49 <212> PRT <213> Artificial Sequence <220> <223> Trail-R3-Fc fusion protein of Trail-R3 extracellular domain (AA 201-236; "repeats" included) and huIgG1 (AA 99-120) with an overlapping amino acid (TRAIL-R3 AA 231 and hulgG1 AA 102) <220> <223> Description of Artificial Sequence: fusion protein <400> 49 Ser Pro Gly Thr Pro Ala Pro Ala Ala Glu Glu Thr Met Thr Ser 15 1 10 5 Pro Gly Thr Pro Ala Pro Ala Ala Glu Glu Thr Met Thr Thr Ser Cys 20 25 30 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 35 40 45 Gly <210> 50 <211> 48 <212> PRT <213> Artificial Sequence <220> <223> Trail-R3-Fc fusion protein of Trail-R3 extracellular domain (AA 201-236; "repeats" included) and huIgG1 (AA 99-120) with an overlapping amino acid (TRAIL-R3 AA 234 and huIgG1 AA 106) <220> <223> Description of Artificial Sequence: fusion protein <400> 50 Ser Pro Gly Thr Pro Ala Pro Ala Ala Glu Glu Thr Met Thr Ser 1 5 15 10

Pro Gly Thr Pro Ala Pro Ala Ala Glu Glu Thr Met Thr Thr Ser Pro

Gly Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly

25

20

35

45

<210> 51 <211> 44 <212> PRT <213> Artificial Sequence <220> <223> Trail-R3-Fc fusion protein of Trail-R3 extracellular domain (AA 201-236; "repeats" included) and huIgG1 (AA 99-120) with an overlapping amino acid (TRAIL-R3 AA 230 and hulgG1 AA 106) <220> <223> Description of Artificial Sequence: fusion protein <400> 51 Ser Pro Gly Thr Pro Ala Pro Ala Ala Glu Glu Thr Met Thr Ser 15 1 5 10 Pro Gly Thr Pro Ala Pro Ala Ala Glu Glu Thr Met Thr His Thr 25 20 30 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 35 40 <210> 52 <211> 43 <212> PRT <213> Artificial Sequence <220>. <223> Trail-R3-Fc fusion protein of Trail-R3 extracellular domain (AA 201-236; "repeats" included) and huIgG1 (AA 99-120) with an overlapping amino acid (TRAIL-R3 AA 229 and huIgG1 AA 106) <220> <223> Description of Artificial Sequence: fusion protein <400> 52 Ser Pro Gly Thr Pro Ala Pro Ala Ala Glu Glu Thr Met Thr Thr Ser 1 10 15 5

Pro Gly Thr Pro Ala Pro Ala Ala Glu Glu Thr Met Thr His Thr Cys

25

20

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly

35 40

<210> 53

<211> 41

<212> PRT

<213> human

<220>

<400> 53

Ser Pro Glu Met Cys Arg Lys Cys Ser Arg Cys Pro Ser Gly Glu Val 1 5 10

Gln Val Ser Asn Cys Thr Ser Trp Asp Asp Ile Gln Cys Val Glu Glu 25 30

Phe Gly Ala Asn Ala Thr Val Glu Thr
35

<210> 54

<211> 61

<212> PRT

<213> Artificial Sequence

<220>

<223> Trail-R3-Fc fusion protein of Trail-R3
 extracellular domain (AA 121-161; "repeats"not
 included) and huIgG1 (AA 99-120) with an
 overlapping amino acid (TRAIL-R3 AA 160 and
 huIgG1 AA 99)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 54

Ser Pro Glu Met Cys Arg Lys Cys Ser Arg Cys Pro Ser Gly Glu Val 1 5 10

Gln Val Ser Asn Cys Thr Ser Trp Asp Asp Ile Gln Cys Val Glu Glu 20 25 . 30

Phe Gly Ala Asn Ala Thr Val Glu Pro Lys Ser Cys Asp Lys Thr His
35 40 45

Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 50 · 55 60

<210> 55

<211> 53

<212> PRT

<213> Artificial Sequence

<220>

ş ,3

<223> Trail-R3-Fc fusion protein of Trail-R3
 extracellular domain (AA 121-161; "repeats"not
 included) and huIgG1 (AA 99-120) with an
 overlapping amino acid (TRAIL-R3 AA 152 and
 huIgG1 AA 99)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 55

Ser Pro Glu Met Cys Arg Lys Cys Ser Arg Cys Pro Ser Gly Glu Val . 1 5 10 15

Gln Val Ser Asn Cys Thr Ser Trp Asp Asp Ile Gln Cys Val Glu Glu 25 30

Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
35 40 45

Glu Leu Leu Gly Gly 50

<210> 56

<211> 52

<212> PRT

<213> Artificial Sequence

<220>

<223> Trail-R3-Fc fusion protein of Trail-R3
 extracellular domain (AA 121-161; "repeats"not
 included) and huIgG1 (AA 99-120) with an
 overlapping amino acid (TRAIL-R3 AA 151 and huIgG1
 AA 99)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 56

Ser Pro Glu Met Cys Arg Lys Cys Ser Arg Cys Pro Ser Gly Glu Val 1 5 10

Gln Val Ser Asn Cys Thr Ser Trp Asp Asp Ile Gln Cys Val Glu Pro 20 25 30

Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 35 40 45

Leu Leu Gly Gly

```
<210> 57
<211> 55
<212> PRT
<213> Artificial Sequence
<220>
<223> Trail-R3-Fc fusion protein of Trail-R3
      extracellular domain (AA 121-161; "repeats"not
      included) and huIgG1 (AA 99-120) with an
      overlapping amino acid (TRAIL-R3 AA 161 and
      huIgG1 AA 106)
<220>
<223> Description of Artificial Sequence: fusion protein
<400> 57
Ser Pro Glu Met Cys Arg Lys Cys Ser Arg Cys Pro Ser Gly Glu Val
  1
                                                          15
                                      10
Gln Val Ser Asn Cys Thr Ser Trp Asp Asp Ile Gln Cys Val Glu Glu
             20
                                  25
                                                      30
Phe Gly Ala Asn Ala Thr Val Glu Thr His Thr Cys Pro Pro Cys Pro
         35
                             40
                                                  45
Ala Pro Glu Leu Leu Gly Gly
     50
                          55
<210> 58
<211> 52
<212> PRT
<213> Artificial Sequence
<220>
<223> Trail-R3-Fc fusion protein of Trail-R3
      extracellular domain (AA 121-161; "repeats"not
      included) and huIgG1 (AA 99-120) with an
      overlapping amino acid (TRAIL-R3 AA 158 and
      huIgG1 AA 106)
<220>
<223> Description of Artificial Sequence: fusion protein
<400> 58
Ser Pro Glu Met Cys Arg Lys Cys Ser Arg Cys Pro Ser Gly Glu Val
                                                          15
  1
Gln Val Ser Asn Cys Thr Ser Trp Asp Asp Ile Gln Cys Val Glu Glu
             20
                                  25
                                                      30
```

Phe Gly Ala Asn Ala Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu

45

40

Leu Leu Gly Gly

<210> 59

<211> 386

<212> PRT

<213> human .

<220>

<223> Trail-R4>sp/Q9UBN6/T10D\_HUMAN Tumor necrosis
 factor receptor superfamily member 10D
 precursor; Decoy receptor 2; DcR2; TNF-related
 apoptosis-inducing ligand receptor 4)

<400> 59

Met Gly Leu Trp Gly Gln Ser Val Pro Thr Ala Ser Ser Ala Arg Ala 1 5 10 15

Gly Arg Tyr Pro Gly Ala Arg Thr Ala Ser Gly Thr Arg Pro Trp Leu
20 25 30

Leu Asp Pro Lys Ile Leu Lys Phe Val Val Phe Ile Val Ala Val Leu 35 40 45

Leu Pro Val Arg Val Asp Ser Ala Thr Ile Pro Arg Gln Asp Glu Val
50 60

Pro Gln Gln Thr Val Ala Pro Gln Gln Gln Arg Arg Ser Leu Lys Glu 65 70 75 80

Glu Glu Cys Pro Ala Gly Ser His Arg Ser Glu Tyr Thr Gly Ala Cys
85 90 95

Asn Pro Cys Thr Glu Gly Val Asp Tyr Thr Ile Ala Ser Asn Asn Leu 100 105 110

Pro Ser Cys Leu Leu Cys Thr Val Cys Lys Ser Gly Gln Thr Asn Lys 115 120 125

Ser Ser Cys Thr Thr Thr Arg Asp Thr Val Cys Gln Cys Glu Lys Gly 130 135 140

Ser Phe Gln Asp Lys Asn Ser Pro Glu Met Cys Arg Thr Cys Arg Thr 145 150 150

Gly Cys Pro Arg Gly Met Val Lys Val Ser Asn Cys Thr Pro Arg Ser 165 170 175

Asp Ile Lys Cys Lys Asn Glu Ser Ala Ala Ser Ser Thr Gly Lys Thr 180 185 190

Pro Ala Ala Glu Glu Thr Val Thr Thr Ile Leu Gly Met Leu Ala Ser 195 200 205

Pro Tyr His Tyr Leu Ile Ile Ile Val Val Leu Val Ile Ile Leu Ala 210 225 220 `

250

255

Val Leu Phe Arg Arg Arg Ser Cys Pro Ser Arg Val Pro Gly Ala Glu 260 265 270

245

Asp Asn Ala Arg Asn Glu Thr Leu Ser Asn Arg Tyr Leu Gln Pro Thr 275 280 285

Gln Val Ser Glu Gln Glu Ile Gln Gly Gln Glu Leu Ala Glu Leu Thr 290 295 300

Gly Val Thr Val Glu Ser Pro Glu Glu Pro Gln Arg Leu Leu Glu Gln 305 310 315 320

Ala Glu Ala Glu Gly Cys Gln Arg Arg Leu Leu Val Pro Val Asn 325 330 335

Asp Ala Asp Ser Ala Asp Ile Ser Thr Leu Leu Asp Ala Ser Ala Thr 340 350

Leu Glu Glu Gly His Ala Lys Glu Thr Ile Gln Asp Gln Leu Val Gly 355 360 365

Ser Glu Lys Leu Phe Tyr Glu Glu Asp Glu Ala Gly Ser Ala Thr Ser 370 375 380

Cys Leu 385

<210> 60

<211> 41

<212> PRT

<213> human

<220>

<223> Trail-R4 extracellular domain (AA 171-211)

<400> 60

Asn Cys Thr Pro Arg Ser Asp Ile Lys Cys Lys Asn Glu Ser Ala Ala 1 5 10

Ser Ser Thr Gly Lys Thr Pro Ala Ala Glu Glu Thr Val Thr Thr Ile 20 25 30

Leu Gly Met Leu Ala Ser Pro Tyr His
35 40

```
<211> 59
<212> PRT
<213> Artificial Sequence
<220>
<223> Trail-R4-Fc fusion protein of Trail-R4
      extracellular domain (AA 171-211) and huIgG1 (AA
      99-120) with an overlapping amino acid (TRAIL-R4
      AA 209 and hulgGl AA 100)
<220>
<223> Description of Artificial Sequence: fusion protein
<400> 61
Asn Cys Thr Pro Arg Ser Asp Ile Lys Cys Lys Asn Glu Ser Ala Ala
                                                         15
                                     10
Ser Ser Thr Gly Lys Thr Pro Ala Ala Glu Glu Thr Val Thr Ile
                                                     30
             20
                                 25
Leu Gly Met Leu Ala Ser Pro Lys Ser Cys Asp Lys Thr His Thr Cys
         35
                                                 45
Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
     50
                         55
<210> 62
<211> 56
<212> PRT
<213> Artificial Sequence
<220>
<223> Trail-R4-Fc fusion protein of Trail-R4
      extracellular domain (AA 171-211) and huIgG1 (AA
      99-120) with an overlapping amino acid (TRAIL-R4
      AA 208 and huIgG1 AA 102)
<220>
<223> Description of Artificial Sequence: fusion protein
<400> 62
Asn Cys Thr Pro Arg Ser Asp Ile Lys Cys Lys Asn Glu Ser Ala Ala
                                     10
Ser Ser Thr Gly Lys Thr Pro Ala Ala Glu Glu Thr Val Thr Thr Ile
                                                      30
             20
Leu Gly Met Leu Ala Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
         35
                             40
```

Pro Ala Pro Glu Leu Leu Gly Gly

55

```
<210> 63
```

<211> 45

<212> PRT

<213> Artificial Sequence

<220>

<223> Trail-R4-Fc fusion protein of Trail-R4
 extracellular domain (AA 171-211) and huIgG1 (AA
 99-120) with an overlapping amino acid (TRAIL-R4
 AA 201 and huIgG1 AA 106)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 63

Asn Cys Thr Pro Arg Ser Asp Ile Lys Cys Lys Asn Glu Ser Ala Ala 1 5 10

Ser Ser Thr Gly Lys Thr Pro Ala Ala Glu Glu Thr Val Thr His
20 25 30

Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
35 40 45

<210> 64

<211> 54

<212> PRT

<213> Artificial Sequence

<220>

<223> Trail-R4-Fc fusion protein of Trail-R4
 extracellular domain (AA 171-211) and huIgG1 (AA
 99-120) with an overlapping amino acid (TRAIL-R4
 AA 211 and huIgG1 AA 107)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 64

Asn Cys Thr Pro Arg Ser Asp Ile Lys Cys Lys Asn Glu Ser Ala Ala 1 5 10 15

Ser Ser Thr Gly Lys Thr Pro Ala Ala Glu Glu Thr Val Thr Thr Ile 20 25 30

Leu Gly Met Leu Ala Ser Pro Tyr His Thr Cys Pro Pro Cys Pro Ala 35 40 45

Pro Glu Leu Leu Gly Gly 50

<210> 65

<211> 455

<212> PRT <213> human

<220>

<223> TNF-R1 >sp/P19438/TR1A\_HUMAN necrosis factor
 receptor superfamily member 1A precursor (p60)
 (TNF-R1) (p55) (CD120a) [contains: Tumor necrosis
 factor binding protein 1 (TBPI)]

<400> 65

Met Gly Leu Ser Thr Val Pro Asp Leu Leu Leu Pro Leu Val Leu Leu
1 10 15

Glu Leu Leu Val Gly Ile Tyr Pro Ser Gly Val Ile Gly Leu Val Pro
20 25 30

His Leu Gly Asp Arg Glu Lys Arg Asp Ser Val Cys Pro Gln Gly Lys
35 40 45

Tyr Ile His Pro Gln Asn Asn Ser Ile Cys Cys Thr Lys Cys His Lys 50 55 . 60

Gly Thr Tyr Leu Tyr Asn Asp Cys Pro Gly Pro Gly Gln Asp Thr Asp 65 70 75 80

Cys Arg Glu Cys Glu Ser Gly Ser Phe Thr Ala Ser Glu Asn His Leu 85 90 95

Arg His Cys Leu Ser Cys Ser Lys Cys Arg Lys Glu Met Gly Gln Val

Glu Ile Ser Ser Cys Thr Val Asp Arg Asp Thr Val Cys Gly Cys Arg 115 120 125

Lys Asn Gln Tyr Arg His Tyr Trp Ser Glu Asn Leu Phe Gln Cys Phe 130 135 140

Lys Gln Asn Thr Val Cys Thr Cys His Ala Gly Phe Phe Leu Arg Glu 165 170 175

Asn Glu Cys Val Ser Cys Ser Asn Cys Lys Lys Ser Leu Glu Cys Thr 180 185 190

Lys Leu Cys Leu Pro Gln Ile Glu Asn Val Lys Gly Thr Glu Asp Ser 195 200 205

Gly Thr Thr Val Leu Leu Pro Leu Val Ile Phe Phe Gly Leu Cys Leu 210 220

Leu Ser Leu Leu Phe Ile Gly Leu Met Tyr Arg Tyr Gln Arg Trp Lys 235 240

Ser Lys Leu Tyr Ser Ile Val Cys Gly Lys Ser Thr Pro Glu Lys Glu 245 250 255

Gly Glu Leu Glu Gly Thr Thr Thr Lys Pro Leu Ala Pro Asn Pro Ser 260 . 265 270

Phe Ser Pro Thr Pro Gly Phe Thr Pro Thr Leu Gly Phe Ser Pro Val 275 280 285

Pro Ser Ser Thr Phe Thr Ser Ser Ser Thr Tyr Thr Pro Gly Asp Cys 290 295 300

Pro Asn Phe Ala Ala Pro Arg Arg Glu Val Ala Pro Pro Tyr Gln Gly 305 310 · 315 320

Ala Asp Pro Ile Leu Ala Thr Ala Leu Ala Ser Asp Pro Ile Pro Asn 325 330 335

Pro Leu Gln Lys Trp Glu Asp Ser Ala His Lys Pro Gln Ser Leu Asp 340 345 350

Thr Asp Asp Pro Ala Thr Leu Tyr Ala Val Val Glu Asn Val Pro Pro 355 360 365

Leu Arg Trp Lys Glu Phe Val Arg Arg Leu Gly Leu Ser Asp His Glu 370 380

Ile Asp Arg Leu Glu Leu Gln Asn Gly Arg Cys Leu Arg Glu Ala Gln 385 390 395 400

Tyr Ser Met Leu Ala Thr Trp Arg Arg Arg Thr Pro Arg Arg Glu Ala 405 410 415

Thr Leu Glu Leu Leu Gly Arg Val Leu Arg Asp Met Asp Leu Leu Gly 420 425 430

Cys Leu Glu Asp Ile Glu Glu Ala Leu Cys Gly Pro Ala Ala Leu Pro 435 440 445

Pro Ala Pro Ser Leu Leu Arg 450 455

<210> 66

**1** 3

<211> 41

<212> PRT

<213> human

<220>

<223> TNF-R1 extracellular domain (AA 171-211)

<400> 66

Gly Phe Phe Leu Arg Glu Asn Glu Cys Val Ser Cys Ser Asn Cys Lys
1 5 10 15

Lys Ser Leu Glu Cys Thr Lys Leu Cys Leu Pro Gln Ile Glu Asn Val 20 25 30 Lys Gly Thr Glu Asp Ser Gly Thr Thr 35

<210> 67

1 7

<211> 57

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF-R1-Fc fusion protein of TNF-R1 extracellular
 domain (AA 171-211) and huIgG1 (AA 99-120) with an
 overlapping amino acid (TNF-R1 AA 206 and huIgG1
 AA 99)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 67

Gly Phe Phe Leu Arg Glu Asn Glu Cys Val Ser Cys Ser Asn Cys Lys
1 10 15

Lys Ser Leu Glu Cys Thr Lys Leu Cys Leu Pro Gln Ile Glu Asn Val 20 25 30

Lys Gly Thr Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 35 40 45

Cys Pro Ala Pro Glu Leu Leu Gly Gly 50

<210> 68

<211> 52

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF-R1-Fc fusion protein of TNF-R1 extracellular
 domain (AA 171-211) and huIgG1 (AA 99-120) with an
 overlapping amino acid (TNF-R1 AA 203 and huIgG1
 AA 101)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 68

Gly Phe Phe Leu Arg Glu Asn Glu Cys Val Ser Cys Ser Asn Cys Lys
10 15

Lys Ser Leu Glu Cys Thr Lys Leu Cys Leu Pro Gln Ile Glu Asn Val 20 25 30 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 35 40 45

Leu Leu Gly Gly 50

<210> 69

<211> 48

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF-R1-Fc fusion protein of TNF-R1 extracellular
 domain (AA 171-211) and huIgG1 (AA 99-120) with an
 overlapping amino acid (TNF-R1 AA 203 and huIgG1
 AA 105)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 69

Gly Phe Phe Leu Arg Glu Asn Glu Cys Val Ser Cys Ser Asn Cys Lys
1 10 15

Lys Ser Leu Glu Cys Thr Lys Leu Cys Leu Pro Gln Ile Glu Asn Val 20 25 30

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 35 40 45

<210> 70

<211> 56

<212> PRT

<213> Artificial Sequence

<220>

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 70

Gly Phe Phe Leu Arg Glu Asn Glu Cys Val Ser Cys Ser Asn Cys Lys
1 5 10 15

Lys Ser Leu Glu Cys Thr Lys Leu Cys Leu Pro Gln Ile Glu Asn Val 20 25 30

Lys Gly Thr Glu Asp Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 35 40 45

Pro Ala Pro Glu Leu Leu Gly Gly 50

<210> 71

 $g \in \mathcal{A}$ 

<211> 53

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF-R1-Fc fusion protein of TNF-R1 extracellular
 domain (AA 171-211) and huIgG1 (AA 99-120) with an
 overlapping amino acid (TNF-R1 AA 207 and huIgG1
 AA 104)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 71

Gly Phe Phe Leu Arg Glu Asn Glu Cys Val Ser Cys Ser Asn Cys Lys
1 5 10 15

Lys Ser Leu Glu Cys Thr Lys Leu Cys Leu Pro Gln Ile Glu Asn Val 20 25 30

Lys Gly Thr Glu Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro
45

Glu Leu Gly Gly 50

<210> 72

<211> 55

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF-R1-Fc fusion protein of TNF-R1 extracellular domain (AA 171-211) and huIgG1 (AA 99-120) with an overlapping amino acid (TNF-R1 AA 211 and huIgG1 AA 106)

. <220>

<223> Description of Artificial Sequence: fusion protein

<400> 72

Gly Phe Phe Leu Arg Glu Asn Glu Cys Val Ser Cys Ser Asn Cys Lys
1 10 15

Lys Ser Leu Glu Cys Thr Lys Leu Cys Leu Pro Gln Ile Glu Asn Val 20 25 30

Lys Gly Thr Glu Asp Ser Gly Thr Thr His Thr Cys Pro Pro Cys Pro 35 40 45

Ala Pro Glu Leu Leu Gly Gly 50

<210> 73

£ 5

<211> 54

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF-R1-Fc fusion protein of TNF-R1 extracellular
 domain (AA 171-211) and huIgG1 (AA 99-120) with an
 overlapping amino acid (TNF-R1 AA 210 and huIgG1
 AA 106)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 73

Gly Phe Phe Leu Arg Glu Asn Glu Cys Val Ser Cys Ser Asn Cys Lys
1 5 10 15

Lys Ser Leu Glu Cys Thr Lys Leu Cys Leu Pro Gln Ile Glu Asn Val 20 25 30

Lys Gly Thr Glu Asp Ser Gly Thr His Thr Cys Pro Pro Cys Pro Ala 35 40 45

Pro Glu Leu Leu Gly Gly 50

<210> 74

<211> 461

<212> PRT

<213> human

<220>

<223> TNF-R2 >sp/P20333/TR1B\_HUMAN necrosis factor
 receptor superfamily member 1B precursor (p80)
 (TNF-R2) (p75) (CD120b) [contains: Tumor necrosis
 factor binding protein 2 (TBPII)]

<400> 74

Met Ala Pro Val Ala Val Trp Ala Ala Leu Ala Val Gly Leu Glu Leu

k #

Trp Ala Ala Ala His Ala Leu Pro Ala Gln Val Ala Phe Thr Pro Tyr 20 25 30

Ala Pro Glu Pro Gly Ser Thr Cys Arg Leu Arg Glu Tyr Tyr Asp Gln 35 40 45

Thr Ala Gln Met Cys Cys Ser Lys Cys Ser Pro Gly Gln His Ala Lys
50 55 60

Val Phe Cys Thr Lys Thr Ser Asp Thr Val Cys Asp Ser Cys Glu Asp 65 70 75 80

Ser Thr Tyr Thr Gln Leu Trp Asn Trp Val Pro Glu Cys Leu Ser Cys 85 90 95

Gly Ser Arg Cys Ser Ser Asp Gln Val Glu Thr Gln Ala Cys Thr Arg 100 105 110

Glu Gln Asn Arg Ile Cys Thr Cys Arg Pro Gly Trp Tyr Cys Ala Leu 115 120 125

Ser Lys Gln Glu Gly Cys Arg Leu Cys Ala Pro Leu Arg Lys Cys Arg · 130 135 140

Pro Gly Phe Gly Val Ala Arg Pro Gly Thr Glu Thr Ser Asp Val Val 145 150 155 160

Cys Lys Pro Cys Ala Pro Gly Thr Phe Ser Asn Thr Thr Ser Ser Thr
165 170 175

Asp Ile Cys Arg Pro His Gln Ile Cys Asn Val Val Ala Ile Pro Gly
180 185 190

Asn Ala Ser Met Asp Ala Val Cys Thr Ser Thr Ser Pro Thr Arg Ser 195 200 205

Met Ala Pro Gly Ala Val His Leu Pro Gln Pro Val Ser Thr Arg Ser 210 215 220

Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala Pro Ser Thr Ser 225 230 235 240

Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala Glu Gly Ser Thr Gly 245 250 255

Asp Phe Ala Leu Pro Val Gly Leu Ile Val Gly Val Thr Ala Leu Gly 260 270

Leu Leu Ile Ile Gly Val Val Asn Cys Val Ile Met Thr Gln Val Lys 275 280 285

Lys Lys Pro Leu Cys Leu Gln Arg Glu Ala Lys Val Pro His Leu Pro 290 295 300

Ala Asp Lys Ala Arg Gly Thr Gln Gly Pro Glu Gln Gln His Leu Leu

Ile Thr Ala Pro Ser Ser Ser Ser Ser Ser Leu Glu Ser Ser Ala Ser 325 330 335

Ala Leu Asp Arg Arg Ala Pro Thr Arg Asn Gln Pro Gln Ala Pro Gly 340 345 350

Val Glu Ala Ser Gly Ala Gly Glu Ala Arg Ala Ser Thr Gly Ser Ser 355 360 365

Asp Ser Ser Pro Gly Gly His Gly Thr Gln Val Asn Val Thr Cys Ile 370 375 380

Val Asn Val Cys Ser Ser Ser Asp His Ser Ser Gln Cys Ser Ser Gln 385 390 395 400

Ala Ser Ser Thr Met Gly Asp Thr Asp Ser Ser Pro Ser Glu Ser Pro 405 410 415

Lys Asp Glu Gln Val Pro Phe Ser Lys Glu Glu Cys Ala Phe Arg Ser 420 425 430

Gln Leu Glu Thr Pro Glu Thr Leu Leu Gly Ser Thr Glu Glu Lys Pro
435 440 445

Leu Pro Leu Gly Val Pro Asp Ala Gly Met Lys Pro Ser 450 455 460

<210> 75

4 4

<211> 37

<212> PRT

<213> human

<220>

<223> TNF-R2 extracellular domain (AA 221-257)

<400> 75

Ser Thr Arg Ser Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala 1 5 10 15

Pro Ser Thr Ser Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala Glu 20 25 30

Gly Ser Thr Gly Asp

<210> 76

<211> 53

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF-R2-Fc fusion protein of TNF-R2 extracellular
 domain (AA 221-257) and huIgG1 (AA 99-120) with an
 overlapping amino acid (TNF-R2 AA 252 and huIgG1
 AA 99)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 76

Ser Thr Arg Ser Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala 1 10 15

Pro Ser Thr Ser Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala Glu 20 25 30

Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 35 40 45

Glu Leu Gly Gly 50

<210> 77

<211> 50

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF-R2-Fc fusion protein of TNF-R2 extracellular
 domain (AA 221-257) and huIgG1 (AA 99-120) with an
 overlapping amino acid (TNF-R2 AA 250 and huIgG1
 AA 100)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 77

Ser Thr Arg Ser Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala 1 5 10

Pro Ser Thr Ser Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Lys Ser 20 25 30

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 35 40 45

Gly Gly

50

<210> 78

<211> 49

<212> PRT

<213> Artificial Sequence

<220>

) <sup>1</sup>

<223> TNF-R2-Fc fusion protein of TNF-R2 extracellular
 domain (AA 221-257) and huIgG1 (AA 99-120) with an
 overlapping amino acid (TNF-R2 AA 249 and huIgG1
 AA 100)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 78

Ser Thr Arg Ser Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala 1 5 10 15

Pro Ser Thr Ser Phe Leu Leu Pro Met Gly Pro Ser Pro Lys Ser Cys
20 25 30

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
35 40 45

Gly

<210> 79

<211> 52

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF-R2-Fc fusion protein of TNF-R2 extracellular
 domain (AA 221-257) and huIgG1 (AA 99-120) with an
 overlapping amino acid (TNF-R2 AA 254 and huIgG1
 AA 102)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 79

Ser Thr Arg Ser Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala 1 5 10 15

Pro Ser Thr Ser Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala Glu 20 25 30

Gly Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 35 40 45

Leu Leu Gly Gly

50

<210> 80

<211> 46

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF-R2-Fc fusion protein of TNF-R2 extracellular
 domain (AA 221-257) and huIgG1 (AA 99-120) with an
 overlapping amino acid (TNF-R2 AA 248 and huIgG1
 AA 102)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 80

Ser Thr Arg Ser Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala
1 5 . 10 15

Pro Ser Thr Ser Phe Leu Leu Pro Met Gly Pro Ser Cys Asp Lys Thr 20 25 30

His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
35 40 45

<210> 81

<211> 53

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF-R2-Fc fusion protein of TNF-R2 extracellular
 domain (AA 221-257) and huIgG1 (AA 99-120) with an
 overlapping amino acid (TNF-R2 AA 257 and huIgG1
 AA 104)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 81

Ser Thr Arg Ser Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala 1 5 10 15

Pro Ser Thr Ser Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala Glu 20 25 30

Gly Ser Thr Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 35 40 45

Glu Leu Leu Gly Gly

50

<210> 82

<211> 49

<212> PRT

<213> Artificial Sequence

<220>

<223> TNF-R2-Fc fusion protein of TNF-R2 extracellular
 domain (AA 221-257) and huIgG1 (AA 99-120) with an
 overlapping amino acid (TNF-R2 AA 255 and huIgG1
 AA 106)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 82

Ser Thr Arg Ser Gln His Thr Gln Pro Thr Pro Glu Pro Ser Thr Ala 1 5 10

Pro Ser Thr Ser Phe Leu Leu Pro Met Gly Pro Ser Pro Pro Ala Glu 20 25 30

Gly Ser Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
35 40 45

Gly